Our findings support the results of several genetic studies where the PERK pathway was manipulated and the disease was accelerated, however they contradict the outcomes of a pharmacological study that reported GSK2606414-induced neuroprotection in a prion disease mouse model [26]. This evidence concerns the gene EIF2AK3 and prion disease.